Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
$117.34
-$1.45(-2.47%)
At close: 4:00 PM EST
$117.34
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$49.00 - $117.89
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$3.62B
Enterprise Value$1.73B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 27, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding32,833,400
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio63.44
Price to Book (P/B)13.21
Price to Sales (P/S)0.00
P/FCF Ratio-65.58
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-32.66
Forecast
1Y Price Target
$106.25Price Target Upside-9.45% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionSuccessful completion of recent equity financing has strengthened the company's financial position, potentially supporting future commercial launch.
Regulatory ApprovalThe National Medical Products Administration of China has agreed to accept the New Drug Application with priority review for tinlarebant for the treatment of Stargardt disease.
Trial ResultsThe decision by China's NMPA was based on interim analysis results from the Phase 3 DRAGON trial showing statistical significance in the primary endpoint.
Bears Say
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $117.89 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $3.62B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Mar 27, 2026 which is in 136 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Nov 10, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.488 by -$0.162.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Overvalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.49.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 32,833,400 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.488. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.25 (-9.45% Downside)
$106.25 (-9.45% Downside)
Hedge Fund Trend
Decreased
By 781.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-37.34%
Trailing 12-Months
Asset Growth
32.07%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects significant regulatory progress and strong financial positioning through successful funding. However, these positives are counterbalanced by increased losses and rising expenses, primarily due to share-based compensation and trial costs.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$106.25
▼(-9.45% Downside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
Ownership Overview
7.30%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---